Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, et al.
Archives of Pharmacal Research (2023) Vol. 46, Iss. 5, pp. 361-388
Open Access | Times Cited: 24

Showing 24 citing articles:

Anticancer activities of natural antimicrobial peptides from animals
Baozhen Qu, Jiangshui Yuan, Xueli Liu, et al.
Frontiers in Microbiology (2024) Vol. 14
Open Access | Times Cited: 18
Innovations in Biosensor Technologies for Healthcare Diagnostics and Therapeutic Drug Monitoring: Applications, Recent Progress, and Future Research Challenges
Mohamed Hemdan, Mohamed A. Ali, Ahmed S. Doghish, et al.
Sensors (2024) Vol. 24, Iss. 16, pp. 5143-5143
Open Access | Times Cited: 18
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?
Chen Fu, Weiwei Tong, Lifeng Yu, et al.
Pharmacological Research (2024) Vol. 203, pp. 107160-107160
Open Access | Times Cited: 8
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Zhiwen Huang, Zachary Braunstein, Jun Chen, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 4, pp. 579-598
Open Access | Times Cited: 6
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Implications of inflammatory cell death-PANoptosis in health and disease
Hyun W. Bae, Y.H. Jang, Rajendra Karki, et al.
Archives of Pharmacal Research (2024) Vol. 47, Iss. 7, pp. 617-631
Closed Access | Times Cited: 4
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment
Gloria Lalli, Ilaria Sabatucci, Mariachiara Paderno, et al.
Targeted Oncology (2025)
Closed Access
Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress
Vlad Iova, R.C. Tincu, Ioana Scrobotă, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 981-981
Open Access
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Shivangi Kumari, Sonam Raj, M. Arockia Babu, et al.
Archives of Pharmacal Research (2023) Vol. 47, Iss. 1, pp. 40-65
Closed Access | Times Cited: 9
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)
Ethan S. Lindgren, Rongshan Yan, Onur Çil, et al.
Current Ophthalmology Reports (2024) Vol. 12, Iss. 2, pp. 13-22
Open Access | Times Cited: 3
Current Status and Future Perspectives of Antibody–Drug Conjugates in Hormone Receptor-Positive Breast Cancer
Maria Grammoustianou, Foteinos‐Ioannis Dimitrakopoulos, Angelos Koutras
Cancers (2024) Vol. 16, Iss. 10, pp. 1801-1801
Open Access | Times Cited: 2
Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
Kaili Mao, Ping Chen, HuaYu Sun, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges
Mei Peng, Xuetong Chu, Yan Peng, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 6
Antibody-Drug Conjugates and Ocular Toxicity
Mustafa Jaffry, Hassaam S. Choudhry, Owais M. Aftab, et al.
Journal of Ocular Pharmacology and Therapeutics (2023) Vol. 39, Iss. 10, pp. 675-691
Closed Access | Times Cited: 5
Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
Sandeep Sherawat, Suraj H. Shinde, Sakeel Ahmed, et al.
Immunology (2023) Vol. 171, Iss. 4, pp. 464-496
Open Access | Times Cited: 5
From Formation to Detection: Understanding Monoclonal Antibody Aggregation through Analytical Lenses
Ajay Pakalapati, Aluru Ranganadhareddy, Narra Naga Pavan Kumar
Journal Of Biochemical Technology (2024) Vol. 15, Iss. 2, pp. 27-32
Open Access | Times Cited: 1
Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Sébastien Tabariès, Alma Robert, Anne Marcil, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1459-1470
Closed Access | Times Cited: 1
Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker
Lydia Bisbal Lopez, Domenico Ravazza, Matilde Bocci, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 2
A native SEC-MS workflow and validation for analyzing drug-to-antibody ratio and drug load distribution in cysteine-linked antibody-drug conjugates
Gang Wu, Chuanfei Yu, Sicheng Yin, et al.
Journal of Chromatography B (2024) Vol. 1241, pp. 124167-124167
Closed Access
Research Progress of Antibody-Oligonucleotide Conjugates
瑶 孙
Pharmacy Information (2024) Vol. 13, Iss. 02, pp. 82-91
Closed Access
Advances in conjugate drug delivery System: Opportunities and challenges
Yishen Zhu, Jiaqi Wu, Feng Zhi
International Journal of Pharmaceutics (2024) Vol. 667, pp. 124867-124867
Closed Access
Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives
Sharada Sawant, Gaurav Gopal Naik, Alakh N. Sahu, et al.
Medical Oncology (2024) Vol. 41, Iss. 12
Closed Access
Page 1

Scroll to top